With 88342.0 shares changed hands, the volume of the stock remained heavier than its average volume of 63760.0 shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $2.05 whereas the lowest price it dropped to was $1.9201. The 52-week range on MDXH shows that it touched its highest point at $3.50 and its lowest point at $1.35 during that stretch. It currently has a 1-year price target of $5.55. Beta for the stock currently stands at 0.56.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MDXH was down-trending over the past week, with a drop of -2.87%, but this was down by -1.93% over a month. Three-month performance surged to 28.48% while six-month performance fell -15.42%. The stock lost -27.76% in the past year, while it has lost -14.35% so far this year. A look at the trailing 12-month EPS for MDXH yields -1.15 with Next year EPS estimates of -0.22. For the next quarter, that number is -0.12. This implies an EPS growth rate of 58.96% for this year and 53.86% for next year.
Float and Shares Shorts:
At present, 49.50 million MDXH shares are outstanding with a float of 38.41 million shares on hand for trading. On 2025-05-30, short shares totaled 41102.0, which was 8.0 higher than short shares on 1745971200. In addition to Mr. Michael K. McGarrity as the firm’s CEO & Executive Director, Mr. Ron Kalfus CPA serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.43043998 of MDXH’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, MDXH reported revenue of $24292000.0 and operating income of -$4588000.0. The EBITDA in the recently reported quarter was -$1649000.0 and diluted EPS was -$0.19.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MDXH since 11 analysts follow the stock currently. There are 9 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With MDXH analysts setting a high price target of 7.0 and a low target of 4.2, the average target price over the next 12 months is 5.55. Based on these targets, MDXH could surge 244.83% to reach the target high and rise by 106.9% to reach the target low. Reaching the average price target will result in a growth of 173.4% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.15101 being high and -$1.24518 being low. For MDXH, this leads to a yearly average estimate of -$1.20333. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
